Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study will provide an evaluation of biologic markers of leukemia cell response following
a single dose of copanlisib prior to any salvage induction therapy in a projected cohort of
10 relapsed/refractory B-ALL patients.